Stealth Bio posts plans for $86M IPO; Sanofi out-li­cens­es drug for neu­roen­docrine-re­lat­ed dis­ease

→ New­ton, MA-based Stealth Bio­Ther­a­peu­tics joined the queue of biotechs look­ing to jump in­to Nas­daq in ear­ly 2019. The com­pa­ny is fo­cused on mi­to­chon­dr­i­al dys­func­tion, list­ing plans to raise $86 mil­lion. Morn­ing­side Ven­ture con­trols 95.3% of the eq­ui­ty.

→ Lit­tle Ac­er Ther­a­peu­tics $AC­ER has in-li­censed a non-pep­tide tachykinin NK3 re­cep­tor drug called os­ane­tant from Sanofi with plans to de­vel­op it for neu­roen­docrine-re­lat­ed dis­or­ders. Ac­er CEO Chris Schelling tout­ed the drug’s “ro­bust non-clin­i­cal, phar­ma­co­ki­net­ic and hu­man safe­ty da­ta.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.